[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scad":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,76,97,125,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100646941","phase-4-spontaneous-coronary-artery-dissection---antiplatelet-therapy-intensity-in-guided-conservative-management-scad-align-trial-100646941",false,"NCT07683923","Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial","Spontaneous Coronary Artery Dissection - Antiplatelet Therapy Intensity in Guided Conservative Management (SCAD-ALIGN) Trial","SCAD-ALIGN","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Presentation with an Acute Coronary Syndrome.\n3. Suspected SCAD on coronary angiography (determined by the local investigator).\n4. Planned conservative treatment of SCAD.\n5. Intensive as well as moderate treatment of SCAD is possible.\n6. Ability to understand the patient information and to personally sign and date the informed consent to participate in the study, before completing any study-related procedures.\n7. The patient is cooperative and available for the entire study.\n8. Written and informed consent.\n9. For women of childbearing potential: Patient is willing to use adequate contraceptive precautions during the study (until 12 Month FU)\n\nExclusion Criteria:\n\n1. Hypersensitivity to the study medication.\n2. Any indication for oral anticoagulation.\n3. Any indication for APT (including thienopyridines, non-thienopyridines, ASA and other anti-thrombotic agents) other than SCAD.\n4. Cardiogenic shock at the time of screening.\n5. Coronary artery disease (CAD) requiring secondary preventive therapy with APT.\n6. Life threatening bleeding (BARC type ≥3) at the time of screening.\n7. Active bleeding, such as peptic ulcer, tumor bleeding or intracranial hemor-rhage at the time of screening.\n8. History of major bleeding, BARC class ≥3 within 3 months before study in-clusion.\n9. Known bleeding diathesis.\n10. Known coagulopathy or refusal of blood transfusion.\n11. Planned surgery or intervention at high bleeding risk during the study period.\n12. Co-administration of contraindicated medications as follows: other P2Y12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral antico-agulants, or chronic therapy with subcutaneous anticoagulants); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg\u002Fweek); lithium.\n13. Known pregnancy or lactation.\n14. Current participation in another clinical trial with drugs or medicinal products.","ALL","18 Years",{"count":20,"type":21},3518,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome in which blood flow to the heart muscle is reduced or interrupted. It predominantly affects women between 30 and 55 years of age and typically occurs in the absence of atherosclerosis. For many years, SCAD remained underdiagnosed and has only recently been more systematically recognised. The SCAD-ALIGN trial will be the first randomised study to systematically compare two antiplatelet treatment strategies in patients with SCAD.\n\nSCAD is usually not associated with significant atherosclerosis or the classic vessel occlusion caused by a blood clot. Instead, bleeding occurs within the wall of a coronary artery, causing the vessel layers to separate and thereby impairing or completely obstructing blood flow. Patients develop symptoms of acute myocardial infarction, such as chest pain, shortness of breath, or nausea. A characteristic feature is that these symptoms often occur in individuals without a prior history or risk of heart disease.\n\nPlatelets play a crucial role in blood clotting but can also accumulate inside blood vessels and further impair flow. Antiplatelet medications are used to prevent this. In current clinical practice, SCAD patients are often treated according to general guidelines for acute coronary syndrome, which typically include two different antiplatelet therapies, a strategy developed and tested in older patients with proven atherosclerosis.\n\nThe SCAD-ALIGN trial is based on a fundamental difference between SCAD and classic heart attacks. In typical heart attacks, a blood clot usually blocks a vessel, and after the implantation of a vascular support device (\"stent\"), intensive antiplatelet therapy is used to prevent further clot formation. In SCAD, however, the underlying problem is a tear or bleeding within the vessel wall. In this situation, intensive antiplatelet therapy could delay the resolution of the bleeding or even worsen it, thereby adversely affecting the course of the disease. The study will therefore investigate whether a less intensive treatment strategy may be more beneficial in these patients.\n\nThe SCAD-ALIGN trial compares two treatment strategies: moderate antiplatelet therapy with a single medication for three months versus more intensive therapy with two agents for three months, followed by nine months of treatment with a single medication. The primary endpoint is a composite of recurrent myocardial ischemia, recurrent SCAD, myocardial infarction, the need for revascularization, and death.\n\nThe SCAD-ALIGN trial is part of the Multinational Clinical Trials Initiative of the Global Cardiovascular Research Funders Forum (GCRFF). The study is designed as an international, multicentre, randomised, open-label clinical trial. Because SCAD is a rare condition, close collaboration across national borders is essential. The results are expected to make an important contribution to the development of evidence-based treatment recommendations for SCAD, improve care and quality of life for patients worldwide.",[27,28],"SCAD","ACS (Acute Coronary Syndrome)",[27,30,31,32,33,34,35],"ACS","APT","MACE","DAPT","spontaneous coronary artery dissection","Antiplatelet therapy","NOT_YET_RECRUITING","2026-06-28",{"date":39,"type":40},"2026-07-06","ACTUAL",{"date":42,"type":21},"2027-03-01",{"date":44,"type":21},"2033-02-28",{"name":46,"class":47},"Universitätsklinikum Hamburg-Eppendorf","OTHER",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100165474","genetic-investigations-in-spontaneous-coronary-artery-dissection-scad-100165474","NCT01427179","Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)","Inclusion Criteria:\n\n* Men and women able to give informed consent and complete a 2 page questionnaire\n* Diagnosis of one or more episodes of spontaneous coronary artery dissection (SCAD)\n* Biological parent of individual with SCAD\n* Relative with fibromuscular dysplasia, arterial aneurysm, or arterial dissection\n\nExclusion Criteria:\n\n* Lack of confirmation of SCAD diagnosis",true,{"count":57,"type":21},2000,"15 Years","OBSERVATIONAL","The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause spontaneous coronary artery dissection (SCAD), in other words, spontaneous tears in blood vessels that supply the heart.\n\nSome mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person.",[62,27],"Spontaneous Coronary Artery Dissection",[64,27],"Spontaneous coronary artery dissection","RECRUITING","2026-04-10",{"date":68,"type":40},"2026-04-15",{"date":70,"type":4},"2011-05",{"date":72,"type":21},"2030-12",{"name":74,"class":47},"Mayo Clinic",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":27,"eligibilityCriteria":81,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":96,"locationsCount":75},"100165668","the-virtual-multicenter-spontaneous-coronary-artery-dissection-scad-registry-100165668","NCT01429727","The \"Virtual\" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry","Inclusion Criteria:\n\n* Individuals who have been cared for at Mayo Clinic with a diagnosis of SCAD\n* SCAD in women who are pregnant or within 12 months postpartum at the time of SCAD\n* SCAD in individuals who self-identify as a member of a racial or ethnic group that is currently underrepresented in the registry. This would include anyone who identifies as: Black\u002FAfrican American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and any race with Hispanic ethnicity\n* SCAD in a man\n* SCAD in persons younger than 30 years of age\n* SCAD within the past 2 weeks (acute)\n* SCAD patient enrolling into any other Mayo Clinic SCAD Research Study\n* SCAD in individuals who have a relative that has had a SCAD event\n\nPersons with history of SCAD who are interested in participating in the study but do not meet the updated inclusion criteria will not be enrolled at this time. However, they will be given the option to share their contact information in order to be invited to future Mayo Clinic SCAD studies.",{"count":83,"type":21},2500,"The primary goal of this project is to describe the clinical and physiologic characteristics of Spontaneous Coronary Artery Dissections (SCAD) in order to increase awareness, understanding, treatment and prevention of a potentially fatal cardiovascular event.\n\nThis study will be a retrospective and prospective review of medical course and current health of men and women with SCAD.",[62,27],[64,27,87,88,89],"coronary artery disease","myocardial infarction","coronary dissection","2026-01-21",{"date":92,"type":40},"2026-01-23",{"date":94,"type":4},"2011-07",{"date":72,"type":21},{"name":74,"class":47},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100617338","norwegian-spontaneous-coronary-artery-dissection-study-100617338","NCT07317323","Norwegian Spontaneous Coronary Artery Dissection Study","Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD Study)","NOR-SCAD","Inclusion Criteria:\n\n* Spontaneous coronary artery dissection\n\nExclusion Criteria:\n\n* Severe kidney failure\n* Severe allergic reaction to contrast",{"count":106,"type":21},300,"The Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD) is a national, multicenter prospective observational study conducted at major hospitals in Norway. The study investigates risk factors and complications of spontaneous coronary artery dissection (SCAD). Patients aged 18 years or older who are hospitalized with SCAD are recruited during the index hospitalization. Each participant will be followed for 52 weeks with scheduled visits at 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac assessments, genetic analyses, blood sampling, structured questionnaires, and a cardiopulmonary exercise test (CPET).",[27,109,110],"Myocardial Infarction (MI)","Women",[112,103,113,114],"SCAD NORGE","Spontan Koronar arteriedisseksjon studie","Norwegian Spontaneous Coronary artery dissection study","2025-12-18",{"date":117,"type":40},"2026-01-05",{"date":119,"type":40},"2025-04-01",{"date":121,"type":21},"2035-12-31",{"name":123,"class":47},"Oslo University Hospital",3,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":75},"100574437","phase-4-impact-of-cyp2c19-genotype-guided-approach-in-antiplatelet-therapy-on-platelet-reactivity-index-among-coronary-artery-disease-cad-patients-100574437","NCT06759272","Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","Pharmacogenomic Markers of Clopidogrel Resistance in Malaysian CAD Patients: Clinical Efficacy and Economic Evaluation of CYP2C19 Genotype-Guided Therapy","Inclusion Criteria:\n\n* Males or females\n* Aged between 18 to 80 years old\n* Patients presents with stable CAD or acute coronary syndrome (ACS)\n* Eligible for percutaneous coronary intervention (PCI)\n* Willing to provide DNA sample via blood drawn for genotyping and platelet reactivity assessment\n* Willing and able to provide informed written consent\n\nExclusion Criteria:\n\n* Primary PCI or rescue PCI\n* Any urgent\u002Femergent coronary angiography procedure that would not allow for genetic testing to be performed before PCI\n* Failure of index PCI\n* Patient or physician refusal to enroll in the study\n* Patient with known CYP2C19 genotype prior to randomization\n* Planned revascularization of any vessel within 30 days post-index procedure and\u002For of the target vessel(s) within 12 months post-procedure\n* Anticipated discontinuation of clopidogrel or ticagrelor within the 12 months follow up period (e.g. for elective surgery)\n* History of ischaemic or haemorrhagic stroke\n* History of allergies to aspirin, ticagrelor, or clopidogrel\n* Suffering from HIV or any blood transmitted disease.\n* Considered at high risk of bleeding\\*\n* Stage 5 chronic kidney disease (CKD) based on the National Kidney Foundation, Kidney disease quality outcome initiative (KDQOI) definition (Levey et al., 2005), or those who were on haemodialysis\n* Pre-existing liver cirrhosis\n* Pregnant women at any stage of gestation\n* Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematous, etc.)\n* Patient is receiving chronic anticoagulation therapy (i.e. vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)\n* Concomitant use of simvastatin\u002Flovastatin \\>40 mg qd\n* Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)\n* Non-cardiac condition limiting life expectancy to less than a year, per judgement of physician","80 Years",{"count":134,"type":21},120,[24],"The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in coronary artery disease patients. It will also learn about the comparison between clopidogrel and ticagrelor.\n\nThe main questions it aims to answer are:\n\nTo compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on platelet reactivity.\n\nTo compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on the risk of major adverse cardiovascular events (MACE) among newly recruited stable CAD patients.\n\nParticipants will:\n\nTake drug clopidogrel or ticagrelor, based on the random group allocation every day for 1 month. One group of patients will undergone CYP2C19 genetic test for genotype-guided antiplatelet therapy, whether clopidogrel or ticagrelor.\n\nVisit the clinic post 30 days of PCI for follow-ups and platelet function tests.",[138,28,27],"Coronary Arterial Disease (CAD)",[140],"CYP2C19 genotype-guided antiplatelet therapy","2025-01-04",{"date":143,"type":40},"2025-01-07",{"date":145,"type":21},"2025-02",{"date":147,"type":21},"2026-02",{"name":149,"class":47},"Nur Hafizah Annezah binti Utuh",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":75},"100432072","canadian-scad-study-100432072","NCT04906356","Canadian SCAD Study","Canadian Spontaneous Coronary Artery Dissection (SCAD) Study and Genetic Sub-study (Prospective, Observational Registry With 10 Year Follow-up)","Inclusion Criteria:\n\n1. Patients admitted with ACS (STEMI, NSTEMI or unstable angina)\n2. Documented SCAD on a coronary angiogram (including diagnosis with OCT or IVUS)\n\nExclusion Criteria:\n\n1\\. Patients where SCAD is attributed to atherosclerotic coronary artery disease, with atherosclerotic coronary artery disease stenosis ≥50%",{"count":158,"type":21},3000,"Natural history multicenter, prospective, observational registry with 10-year follow-up",[62,27,161],"Fibromuscular Dysplasia",[163,164,165,166,167,27,62],"Fibromuscular displasia (FMD)","Myocardial Infarction","Myocardial Infarction in women","Non-atherosclerotic coronary artery disease (NACAD)","Myocardial Infarction with no obstructive coronary artery disease (MINOCA)","2021-05-25",{"date":170,"type":40},"2021-05-28",{"date":172,"type":40},"2018-12-01",{"date":174,"type":21},"2033-12-01",{"name":176,"class":47},"Cardiology Research UBC"]